

action of these substances. The aim of the present studies was to investigate the influence of MTX and DXR on the central nervous system in the respect of their influence on the seizure susceptibility in chemical and electric convulsions and the modulation of the learning and memory processes in mice.

MATERIAL AND METHODS

The experiments were carried out on male and female Albino Swiss mice (20-25g). Standard food and water were available *ad libitum*. Each experimental group consisted of 12 animals. The central action of two cytostatics: methotrexat (MTX), antimetabolite of folic acid and doxorubicin (DXR), oncostatic antibiotic belonging to antracycline group, was studied. The investigated substances were dissolved in 0.9% NaCl and injected intraperitoneally (*ip*) in single doses 5 or 10 mg/kg. The experiments were performed 14 days after a single injection of drugs, only the passive avoidance task was done after 24 h, 7 and 14 days.

The substances, the solvents used for their dilution and way of administration are listed below: Doxorubicin (Adriablastine, Pharmacia, Italy) was diluted with saline and injected *ip*. Hexobarbital (ZVEB Arzneimittel Verk, Dresden Germany) was dissolved in distilled water and injected *ip*. Methotrexat (Rhone-Poulenc Rorer, France) was dissolved in saline and administered *ip*. Pentetrazole (Sigma, St. Louis) was dissolved in saline and administered *sc*. Pilocarpine (Sigma, St. Louis) was dissolved in saline and administered *ip*. N-methylscopolamine (Sigma, St. Louis) was dissolved in saline and injected *sc*. 15 min prior to pilocarpine. All substances were administered in a constant volume of 5 ml/kg. Control animals received an equivalent volume of solvent. Exact doses of the substances are given under the description of each test.

Pentetrazole seizures in mice were induced by the *s.c.* pentetrazole injection at different doses 14 days after the MTX or DXR administration. Animals were observed during 60 min and the number of mice developing clonic and tonic seizures as well as mortality were recorded. CD_{50} (a dose necessary to produce a 50% effect) of pentetrazole for clonus, tonus and mortality was calculated using the method of Litchfield and Wilcoxon (7).

Pilocarpine seizures in mice were induced by the pilocarpine administration at the dose of 380 mg/kg *ip* 14 days after the MTX or DXR treatment. 15 min before pilocarpine administration mice received N-methyl-scopolamine (1 mg/kg *s.c.*), blocker of peripheral muscarinic receptors. Animals were observed during 60 min and the latency time in min to the development of limbic and clonic seizures was recorded. Data were calculated as means \pm SEM and evaluated statistically using Student's t-test.

Maximal electroshock was induced by means of alternating current (50 Hz, 25 mA, 0.2 s) with the use of ear clip electrodes according to the method of Swinyard et al. (17). The criterion of the convulsive response was the tonic extension of the hind limbs. The test was performed 14 days after the administration of MTX or DXR. The amount of mice with tonic seizures was noted.

Threshold for electroconvulsions was evaluated by using different values of alternating current (5, 6, 7, or 8 mA, 50 Hz, 0.2 s). The criterion of the convulsive response was the tonic extension of the hind limbs. The test was performed 14 days after the administration of MTX or DXR and CS_{50} (in mA) was calculated using the method of Litchfield and Wilcoxon (7).

Duration of the hexobarbital sleeping time in min was measured after the *ip* administration of hexobarbital at the dose of 100 mg/kg 14 days after the MTX or DXR treatment. Animals were observed for 120 min after the hexobarbital administration. Data were calculated as means \pm SEM and evaluated statistically using Student's t-test.

The step-through passive avoidance task was performed according to Venault et al. (19). Mice were placed in an illuminated box (10 x 13 x 15cm) connected to a large dark box (25x20x15cm) which was equipped with an electric grid floor. The entrance into the dark box was punished by an electric footshock (0.6 mA for 2 s; unscrambled DC current; impairment of acquisition or 0.1 mA for 2 s; facilitation of acquisition). On the next day (24 h), the same mice were placed in the illuminated box. Mice avoiding the dark compartment for over 120 s were considered as remembering the task. Retention was quantified as the number of animals avoiding the dark compartment. The results were evaluated statistically using exact Fischer's test. The experiments were performed 24 h, 7 and 14 days after the MTX or DXR administration. The step-through passive avoidance task may give information about ability to acquire the task (learning) and to recall the task (retrieval) and may be regarded as a measure involving long-term memory.

The animals were decapitated 14 days after the treatment of MTX or DXR, their brains were immediately frozen. The GABA content in brain tissue was measured according to the method of Love et al. (9) with the modification of Sutton and Simmonds (16). Data were expressed in $\mu\text{g/g}$ of tissue as means \pm SEM and evaluated statistically using Student's t-test.

RESULTS

MTX increased the susceptibility of mice to pentetrazole-induced seizures, expressed as the decrease of CD_{50} of PTZ for tonus, clonus and mortality in both administered doses 14 days after the treatment. DXR showed the weak tendency of proconvulsive action for PTZ, but the results were significant only in the case of clonic seizures (Tab. 1).

Both drugs, MTX and DXR, possessed proconvulsive activity in pilocarpine-induced seizures. MTX in both administered doses shortened the latency for limbic and clonic seizures evoked by pilocarpine. DXR at the dose of 5 mg/kg shortened only the latency to clonic convulsions. In a higher dose, 10 mg/kg, had the proconvulsive activity in respect to limbic and clonic seizures (Tab. 2)

Neither MTX nor DXR had the influence on the MES convulsions (Tab. 3). But the threshold for electroconvulsions expressed as CS_{50} was decreased by MTX administered at the doses 5 and 10 mg/kg. DXR did not change the threshold for electroconvulsions (Tab. 4).

MTX shortened the hexobarbital-sleeping time 14 days after single administration in both doses used. DXR did not affect this parameter (Tab.5).

In the passive avoidance task only MTX at the dose 10 mg/kg 14 days after the administration caused the impairment of fresh working memory in mice. DXR had no effect on this parameter (Tab. 6).

MTX decreased the GABA content in mice brain tissue. In the action of DXR the same tendency could be observed, but the differences were not significant (Tab. 7).

Table 1. The influence of MTX and DXR 14 days after treatment on the threshold for pentetrazole-induced seizures in mice (n=12)

Compound	Dose mg/kg	CD ₅₀ for pentetrazole in mg/kg		
		clonus	tonus	mortality
Control	solvent	87.3 [82.0-93.0]	98.5 [86.0-112.7]	98.6 [92.3-105.2]
MTX	5	77.1 [68.0-88.0]*	84.6 (80.3-89.0)*	86.7 [81.4-92.4]**
MTX	10	66.8 [58.4-76.5]***	79.7 [70.7-89.8]*	80.1 [73.0-88.0]***
DXR	5	81.8 [64.1-104.5]	93.3 [83.4-105.8]	95.2 [73.2-123.9]
DXR	10	77.4 [72.0-83.3] *	86.2 [69.4-107.1]	89.4 [77.9-102.6]

*p<0.05; **p<0.01; *** p<0.001 versus control. Litchfield and Wilcoxon.

Table 2. The influence of MTX and DXR 14 days after treatment on the latency time to pilocarpine-induced (380 mg/kg *ip*) seizures in mice (n=12)

Compound	Dose mg/kg	Latency time (min) ~ SEM to appearance of seizures:	
		limbic	clonic
Control	solvent	28.4 ± 2.8	55.7 ± 4.6
MTX	5	17.1 ± 2.2**	31.6 ± 5.7**
MTX	10	15.4 ± 4.1**	20.6 ± 3.5***
DXR	5	20.1 ± 13.9	36.4 ± 3.3**
DXR	10	18.2 ± 3.4*	31.9 ± 14.2**

* p<0.05; ** p<0.01; *** p<0.001 vs control. Student's t-test.

Table 3. The influence of MTX or DXR 14 days after treatment on the seizure activity in maximal electroshock (MES) in mice

Compound	Dose mg/kg	Number of animals with tonic seizures
Control	solvent	12/12
MTX	5	12/12
MTX	10	12/12
DXR	5	12/12
DXR	10	12/12

Table 4. The influence of MTX or DXR 14 days after treatment on the seizure threshold for electroconvulsions in mice (n=12)

Compound	Dose (mg/kg)	CS ₅₀ (mA)
Control	solvent	6.5 [5.7-7.3]
MTX	5	5.3 [4.8-5.7]**
MTX	10	5.2 [4.4-6.1]*
DXR	5	5.7 [5.0-6.4]
DXR	10	5.6 [5.0-6.4]

*p<0.05; **p<0.01; vs control. Litchfield and Wilcoxon.

Table 5. The influence of MTX or DXR 14 days after treatment on the duration of the hexobarbital-induced (100 mg/kg) sleeping time in mice (n=12)

Compound	Dose mg/kg	Sleeping time in min ± SEM
Control	solvent	118.5 ± 7.6
MTX	5	86.7 ± 7.7*
MTX	10	76.2 ± 9.5***
DXR	5	109.6 ± 10.4
DXR	10	100.2 ± 9.1

* p<0.05; *** p<0.001 vs control, Student's t-test.

Table 6. The influence of MTX or DXR 24 h, 7 and 14 days after treatment on the long-term memory in passive avoidance task (n=15)

Compound	Dose mg/kg	Number of mice remembering the task after:		
		24 h	7 days	14 days
Control	solvent	15/ 15	15/ 15	15/ 15
MTX	10	15/15	9/15	4/15**
DXR	10	15/15	12/15	9/15

** p<0.01 vs control, exact Fischer's test.

Table 7. The influence of MTX or DXR 14 days after treatment on the brain GABA content in mice (n=12)

Compound	Dose mg/kg	GABA content in $\mu\text{g}/\text{g}$ tissue \pm SEM
Control	solvent	364.8 \pm 7.4
MTX	5	329.7 \pm 11.2*
MTX	10	289.6 \pm 8.4***
DXR	5	347.8 \pm 9.5
DXR	10	336.4 \pm 12.8

DISCUSSION

Our results indicate that the behavioral effects induced by both investigated drugs are connected with their central action, but the influence of MTX was more pronounced. MTX strongly increased the susceptibility to seizures of mice: decreased the threshold for pentetrazole and for electroconvulsions and prolonged the latency to pilocarpine-induced limbic and clonic seizures. The influence of DXR on the seizure susceptibility is weakly pronounced only as a prolongation of the latency to pilocarpine and decrease of the threshold for pentetrazole-induced clonic seizures.

The investigated oncostatics did not affect the sensitivity of mice to the maximal electroshock.

In addition MTX shortened the hexobarbital-induced sleeping time, decreased the brain GABA content and caused the impairment of the long-term memory in the passive-avoidance task. DXR did not change these parameters.

The proconvulsive action of MTX may depend on the GABA-ergic system. Diminution of the level of this inhibitory neurotransmitter results in the spontaneous seizure activity in the case of the treatment of glutamate decarboxylase inhibitor, 3-mercaptopropionic acid (9, 16). It is well known from human treatment that MTX administered into the spinal fluid in the case of leukemic metastases into CNS can induce seizures (4, 11). Our results indicate that also after *ip* administration proconvulsive properties of MTX are observed. Moreover the action of hexobarbital is connected with the activity of GABA-ergic system (16), and the decrease of GABA content in our study can explain the reduction by MTX the time of sleep induced by hexobarbital.

DXR showed only a weak, not significant tendency to decrease the BABA concentration in the brain tissue and possessed much lower than MTX pro-convulsive activity.

MTX, but not DXR, caused the impairment of the memory examined in the passive avoidance task investigated two weeks after the treatment. It is known that the enhancement of the GABA-ergic activity induced for ex. by benzodiazepines results in the diminution of the learning and memory, and that antagonists of GABA-ergic receptors facilitated learning (19). In the present work we observed the impairment of the recall of the task and parallelly the decrease of the GABA content in the brain after MTX administration. However, the processes of learning and memory are complicated, connected with different neurotransmitters, neuromodulators, and the mechanisms which are involved in their regulation are not clear yet. In our previous studies it was found that MTX increased the activity of the dopaminergic system but decreased the level of NA in mice brain. Also the exploratory activity of animals was diminished (14). The impairment of the recall of the task in passive avoidance test can be connected with the changes of several neurotransmitter systems and could be the result of the large central influence of MTX on different brain structures.

REFERENCES

1. A p r o M. et al.: Gemcitabine – a safety review. *Anti-Cancer Drug*, 9, 191, 1998
2. B u g a t R. et al.: Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. *Eur. J. Cancer Clin Oncol.*, 25, 505, 1989.
3. C h e n C. et al.: Pharmacodynamics of doxorubicin in human prostate. *Clin. Cancer Res.*, 4, 277, 1998.
4. F u j i m o t o S., O g a w a M.: Antitumor activity of mitoxantrone against murine experimental tumor: comparative analysis against various antitumor antibiotics. *Cancer Chemother. Pharmacol.*, 8, 157, 1982.
5. H u b m e n R. et al.: Malabsorption associated with a high-grade-malignant non-Hodgkin's lymphoma, α -heavy-chain disease and immunoproliferative small intestinal disease. *Gastroenterology*, 33, 209, 1995
6. K l e i n r o k Z. et al.: Comparison of pharmacological properties of rubidomycine and its newly synthesised derivatives DR-22 and DR-27 in animals. *Acta Physiol. Pol.*, 38, 386, 1987.
7. L i t c h f i e l d I. T., W i l c o x o n F.: A simplified method of evaluating dose-effect experiments. *J. Pharmacol. Exp. Ther.*, 96, 99, 1949.
8. L o n g B. et al.: Effect of antracycline analogues on the appearance of newly synthesised RNA and messenger RNA in the cytoplasm of erythroleukemia cells. *Molecular Pharmacol.*, 22, 152, 1982.

9. Love I. P. et al.: The fluorimetric measurement of glutamic decarboxylase and its distribution in the brain. *J. Neurochem* 3, 8, 1953.
 10. Nooter K. et al.: Repeated daunomycin administration in rats. Pharmacokinetics and bone marrow toxicity. *Cancer Chemother. Pharmacol.*, 12, 187, 1984.
 11. Parker S. Et al.: Cancer statistics. *Cancer J. Clin.*, 5, 46, 1996
 12. Rangel C. et al.: Experience with weekly doxorubicin (Adriamycin) in hormone-refractory stage D-2 prostate cancer. *Urology*, 39, 577, 1992.
 13. Rosenoff S. et al.: Adriamycin-induced cardiac damage in the mouse: a small animal model of cardiotoxicity. *J. Nat. Cancer Inst.*, 55,191, 1975.
 14. Sieklucka M. et al.: Caentral action of some cytostatics – methotrexat (MTX) and doxorubicin (DXR). Long-term influence on the pain sensitivity and activity of brain dopaminergic system im mice. *Ann. Univ. Mariae Curie-Skłodowska, Sectio D*, vol 53, Lublin 1998.
 15. Streeter D. et al.: Comparative cytotoxicities of various morpholinyl antracyclines. *Cancer Chemother. Pharmacol.*, 14, 160, 1985
 16. Sutton J., Simmonds M.A: Effect of acute and chronic pentobarbitone on the gamma-aminobutyric acid system in rat brain. *Biochem. Pharmacol.*, 23, 1801, 1974.
 17. Swinyard E. A. et al.: Comparative assays of antiepileptic drugs in mice and rats. *J. Pharmacol. Exp. Ther.*, 106, 319, 1952.
 18. Uchida T. et al.: New antitumor antibiotics distrarubicins. *Antibiotics*. 8, 1080, 1983.
 19. Venault P. et al.: Benzodiazepine impair and β -carbolines enhance performance in learning and memory task. *Nature*, 321, 864, 1986.
 20. Zbinden G. et al.: Model system for cardiotoxic effects of antracyclines. *Antibiotics and Chemother.*, 23, 255, 1978.
- Otrz.: 1998.07.12

STRESZCZENIE

Doświadczenia przeprowadzono na białych myszach, samcach i samicach szczepu Albi-no-Swiss. Badano ośrodkowe działanie dwu powszechnie stosowanych klinicznie cytostatyków: metotreksatu (MTX) – antymetabolitu kwasu foliowego i doksorubicyny (DXR, adriablastyny), antybiotyku z grupy antracyklin. Obydwa leki stosowano dootrzewnowo (*ip*) w jednorazowych dawkach 5 i 10 mg/kg, które odpowiadały dawkom stosowanym w leczeniu np. ostrych białaczek w okresie indukcji remisji. Doświadczenia behawioralne wykonywano po 14 dniach, a biochemiczne po 5 godz. i 14 dniach od zastosowania leków. Wykazano, że MTX wywiera działanie prodrżawkowe: obniża CD_{50} dla penetrozolu, skraca czas latencji w drgawkach wywołanych pilokarpiną i obniża próg drżawkowy w drgawkach elektrycznych. Ponadto MTX skraca czas trwania snu wywołanego heksobarbitalem oraz powoduje upośledzenie pamięci odruchu biernego unikania. Powyższe działania MTX mogą zależeć od zmniejszenia aktywności układu GABA-ergicznego, ponieważ zmniejsza on zawartość GABA w tkance mózgowej. Ośrodkowe działanie DXR jest znacznie słabiej wyrażone. Wykazuje ona niewielkie działanie prodrżawkowe w drgawkach wywołanych pentetrazolem i pilokarpiną, pozostając bez wpływu na drżawki elektryczne. Nie zmienia zawartości GABA oraz nie skraca czasu trwania snu heksobarbitalowego. Nie upośledza też pamięci.